Comparative Pharmacology
Head-to-head clinical analysis: SUPPRELIN versus SYNAREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUPPRELIN versus SYNAREL.
SUPPRELIN vs SYNAREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic decapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH) that acts as a potent inhibitor of gonadotropin secretion. Initially stimulates, then suppresses pituitary gonadotropin release (LH and FSH), leading to decreased testosterone and estrogen production.
Synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH). Binds to pituitary GnRH receptors, initially stimulating then desensitizing them, leading to suppressed LH and FSH secretion, decreased gonadal steroid production (estrogen, testosterone).
50 mcg subcutaneously once daily for the first month, then 25 mcg subcutaneously once daily for maintenance. Alternatively, 7.5 mg intramuscularly once monthly.
200 mcg intranasally twice daily (400 mcg total daily dose) for 6 months. Initiate on day 5 of menstural cycle.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours following subcutaneous administration; this supports once-daily dosing.
Terminal elimination half-life: ~3 hours (range 2-5 hours) after intranasal administration; clinically, dosing every 12 hours maintains therapeutic levels.
Primarily renal, with approximately 70-80% of histrelin excreted unchanged in urine; biliary/fecal excretion accounts for about 20-30%.
Renal: ~90% as parent drug and metabolites; fecal: <10%.
Category C
Category C
GnRH Agonist
GnRH Agonist